Interpace announces preliminary Q3 2026 revenue of $10.1-10.4m
Interpace Biosciences recommence Q3 2026 revenue expected to range $10.1M to $10.4M, reflecting ~11-14% quarter-over-quarter growth. The increase highlights a positive momentum in the company's financial trajectory as it prepares to release full results.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed